Tauopathy
Pathway Diagram
Mermaid diagram (expand to render)
Overview
Tauopathy refers to a class of neurodegenerative disorders characterized by the accumulation of hyperphosphorylated tau protein within neurons and glial cells[@ballard2005]. These disorders include Alzheimer's disease (AD), progressive supranuclear palsy (PSP), corticobasal syndrome (CBD), Pick's disease, and chronic traumatic encephalopathy (CTE)[@goedert2017]. The tau protein, encoded by the MAPT (Microtubule-Associated Protein Tau) gene, plays essential roles in microtubule stabilization, axonal transport, and synaptic function[@mandelkow2012].
The fundamental pathology in tauopathies involves the aggregation of tau into insoluble fibrils that form neurofibrillary tangles (NFTs), neuropil threads, and dystrophic neurites. These aggregates disrupt neuronal function through multiple mechanisms including microtubule destabilization, impaired axonal transport, synaptic dysfunction, and eventual neuronal death[@arendt2016].
Tau Protein Biology
The human MAPT gene located on chromosome 17q21.31 encodes the tau protein through alternative splicing of exon 10. Six tau isoforms are expressed in the adult brain, distinguished by the presence of 3 or 4 microtubule-binding repeats (3R or 4R tau) and 0, 1, or 2 N-terminal inserts[@goedert1989]:
- 3R tau isoforms: Exclude exon 10, contain 3 microtubule-binding repeats
- 4R tau isoforms: Include exon 10, contain 4 microtubule-binding repeats
In the normal adult brain, the ratio of 3R to 4R tau is approximately 1:1, reflecting balanced splicing regulation[@sultan2011]. This balance is critical, as dysregulation toward 4R predominance is a hallmark of PSP and CBD, while 3R predominance characterizes Pick's disease.
Tau performs several essential neuronal functions:
Microtubule stabilization: The microtubule-binding repeats (R1-R4) bind to and stabilize microtubules, enabling axonal transport[@weingarten1975].
Axonal transport regulation: Tau modulates the function of motor proteins (kinesin, dynein) that transport cargo along microtubules[@stamer2002].
Synaptic function: Tau localizes to synapses where it participates in neurotransmitter release and synaptic plasticity[@tai2012].
Signal transduction: Tau interacts with various signaling molecules, including Src family kinases and phosphatases[@lee2011].Molecular Mechanisms of Tauopathies
Tau Hyperphosphorylation
Hyperphosphorylation is the primary modification that converts tau from a functional microtubule-stabilizing protein into a pathological aggregation-prone species[@hanger2009]. Over 45 serine, threonine, and tyrosine residues can be phosphorylated on tau, with specific phosphorylation patterns correlating with disease progression.
Key kinases regulating tau phosphorylation:
| Kinase | Primary Sites | Role in Tauopathy |
|--------|---------------|-------------------|
| GSK-3β | Ser202, Thr205, Ser396, Ser404 | Primary tau kinase, hyperactive in AD |
| CDK5 | Ser202, Thr205, Ser235 | Activated in neurodegeneration |
| PKA | Ser262, Ser356, Ser214 | Promotes microtubule detachment |
| DYRK1A | Thr212 | Elevated in AD brain |
| MAPK | Ser396, Ser404 | Stress-activated |
Key phosphatases:
- PP2A: The major phosphatase dephosphorylating tau; its activity is reduced in tauopathies[@sontag2014]
Tau Aggregation
The aggregation of tau into fibrils follows a nucleation-dependent polymerization model[@soto2008]:
Nucleation: Formation of oligomeric tau species requires overcoming an energy barrier. This is accelerated by:
- Hyperphosphorylation at specific sites (Thr231, Ser396)
- Conformational changes exposing hydrophobic hexapeptide motifs (^306^VQIVYK^311^, ^378^VQIVLK^383^)
- Interaction with seeding-competent tau fibrils
Elongation: Addition of monomeric tau to growing fibrils. 4R tau aggregates faster than 3R due to additional hexapeptide motifs in the fourth repeat.
Maturation: Formation of stable, protease-resistant fibrils with cross-β sheet architecture.Tau Strain Diversity
Distinct tau fibril structures (strains) characterize different tauopathies, as revealed by cryo-electron microscopy[@fitzpatrick2017]:
Alzheimer's disease:
- Paired helical filaments (PHFs)
- Straight filaments (SFs)
- 3R and 4R tau combined in filaments
Progressive supranuclear palsy:
- Three-layered helical structure
- C-shaped cross-section
- 4R tau predominant
Corticobasal syndrome:
- Four-layered structure
- More compact conformation
- Variable filament morphologies
Pick's disease:
- Distinct filament architecture
- 3R tau predominant
Classification of Tauopathies
Primary Tauopathies (4R)
These disorders feature predominant 4R tau accumulation:
- Progressive Supranuclear Palsy (PSP): Characterized by Richardson's syndrome, parkinsonism, vertical gaze palsy, and frontal cognitive deficits[@litvan1996]
- Corticobasal Syndrome (CBS): Features asymmetric parkinsonism, apraxia, alien limb phenomenon, and cortical sensory loss[@riley1994]
- Argyrophilic Grain Disease (AGD): Late-onset dementia with argyrophilic grains
Primary Tauopathies (3R)
- Pick's Disease: Frontotemporal dementia with behavioral changes and language impairment[@dickson2012]
- Alzheimer's Disease: Both 3R and 4R tau in neurofibrillary tangles
- Chronic Traumatic Encephalopathy: CTE shows 3R and 4R tau pathology, often with distinctive perivascular tau at the depths of sulci
Tauopathy Mechanisms in Neurodegeneration
Microtubule Dysfunction
Hyperphosphorylated tau loses its ability to bind and stabilize microtubules, leading to:
- Impaired axonal transport
- Cargo accumulation in axons
- Synaptic vesicle depletion
- Ultimately, axonal degeneration[@cash2003]
Axonal Transport Impairment
Tau pathology disrupts both anterograde (kinesin-dependent) and retrograde (dynein-dependent) transport:
- Kinesin binding to tau competes with microtubule binding
- Tau accumulation leads to "traffic jams" in axons
- Mitochondria and other organelles cannot reach synaptic terminals[@mandelkow2003]
Synaptic Dysfunction
Tau aggregates at synapses contribute to:
- Presynaptic vesicle depletion
- Impaired neurotransmitter release
- Postsynaptic receptor mislocalization
- Early cognitive deficits before neuronal loss[@tai2014]
Neuronal Death Mechanisms
Multiple pathways lead to tauopathy-associated neuronal death:
- Apoptosis: Intrinsic pathway activation in tau-bearing neurons
- Necroptosis: RIPK1/3-mediated cell death in some tauopathies
- Autophagic cell death: Failed autophagy leading to aggregation
- Oxidative stress: Mitochondrial dysfunction and ROS accumulation
Genetic Factors in Tauopathies
MAPT Mutations
The MAPT gene on chromosome 17q21.31 encodes tau and numerous mutations cause or predispose to tauopathies[@rademakers2005]. Over 50 pathogenic MAPT mutations have been identified:
Splicing mutations (alter tau isoform ratios):
- P301L/S: Most common, causes frontotemporal dementia with parkinsonism (FTDP-17)
- exon 10 + 16: Causes 4R tau predominance
- exon 10 - 2: Causes 3R tau predominance
Aggregation-promoting mutations:
- K280: Increases tau filament formation
- S305S: Affects exon 10 splicing
- Q336H: Enhances aggregation propensity
H1 Haplotype
The H1 haplotype of MAPT (a 500 kb inversion polymorphism) is strongly associated with PSP, CBD, and AGD[@pike2021]. The H1c sub-haplotype specifically increases risk for PSP with an odds ratio of approximately 5.5. This haplotype influences MAPT expression and alternative splicing, favoring 4R tau production.
GWAS Findings
Genome-wide association studies have identified multiple tauopathy risk loci[@ferrari2014]:
- MAPT: Strongest association (H1 haplotype)
- MOBP: Myelin-associated oligodendrocyte basic protein
- DUSP10: Dual specificity phosphatase 10
- SLCO1A2: Solute carrier organic anion transporter
- STX6: Syntaxin 6
Epigenetic Regulation in Tauopathy
DNA Methylation
Tauopathy is associated with widespread DNA methylation changes[@de2019]:
- Global hypomethylation in AD brain tissue
- Gene-specific changes at tau-related genes
- Age-related methylation drift exacerbates tau pathology
- APP promoter methylation affects amyloid processing
Histone Modifications
Histone acetylation and methylation patterns are altered in tauopathies:
- Reduced H3K9ac at synaptic genes correlates with cognitive decline
- Increased H3K27me3 at tau kinase promoters
- HDAC inhibitor therapy shows promise in preclinical models
Non-Coding RNAs
MicroRNAs (miRNAs) regulate tau pathology[@siedleckiwullich2019]:
- miR-124: Reduced in AD; restores neuronal glutamate transport
- miR-132: Downregulated in tauopathy; regulates tau phosphorylation
- miR-219: Targets GSK3β mRNA
- miR-146a: Upregulated in AD; promotes inflammation
Long non-coding RNAs (lncRNAs):
- MALAT1: Altered in AD; regulates synaptic plasticity
- NEAT1: Promotes tau aggregation
Tauopathy is closely linked to metabolic dysfunction[@butterfield2019]:
- Brain glucose hypometabolism precedes clinical symptoms in AD
- Insulin signaling impairment exacerbates tau pathology
- Type 2 diabetes increases AD risk 1.5-2 fold
Key mechanisms:
- IRS-1 serine phosphorylation disrupts insulin signaling
- Akt/mTOR pathway dysregulation affects protein synthesis
- AMPK reduced activation impairs energy homeostasis
Mitochondrial Dysfunction
Mitochondria are severely affected in tauopathies:
- Reduced complex IV activity in AD and PSP
- Increased mtDNA mutations with age
- Impaired mitochondrial dynamics (fusion/fission)
- Tau accumulation in mitochondria disrupts function
Therapeutic implications:
- Mitochondrial antioxidants (MitoQ, CoQ10) being studied
- PGC-1α activators promote mitochondrial biogenesis
Insulin Signaling
Brain insulin resistance is a key feature[@kellar2020]:
- Intranasal insulin improves memory in AD trials
- GLP-1 agonists reduce tau phosphorylation in models
- SGLT2 inhibitors may provide neuroprotective effects
Sleep Disorders and Tauopathy
Bidirectional Relationship
Sleep disruption and tauopathy have a bidirectional relationship[@ju2017]:
- Sleep deprivation increases CSF tau levels by 30-50%
- Tau pathology disrupts sleep-wake cycles
- Orexin system dysregulation contributes to sleep fragmentation
Circadian Rhythm Disruption
The suprachiasmatic nucleus is affected in tauopathies:
- BMAL1 clock gene expression reduced in AD
- Peripheral clock genes show altered rhythms
- Melatonin secretion declines with age and tauopathy
Therapeutic Implications
Sleep interventions may benefit tauopathy:
- Sleep hygiene improves tau clearance via glymphatic system
- Orexin antagonists (suvorexant) being studied
- Continuous positive airway pressure (CPAP) for sleep apnea improves cognition
Advanced Diagnostic Approaches
Tau PET Imaging
Tau PET ligands enable in vivo visualization of tau pathology[@leuzy2019]:
FDA-approved ligands:
- Flortaucipir (AV-1451): Binds to PHF tau in AD
- PI-2620: Detects 3R and 4R tau
Emerging ligands:
- APN-1608: Superior off-target binding profile
- Lu-AV-145: Longer half-life for production
Limitations:
- Off-target binding to monoamine oxidase
- Variable binding in different brain regions
- Limited sensitivity for non-AD tauopathies
Cerebrospinal Fluid Biomarkers
CSF analysis provides molecular profiling[@blennow2021]:
Tau species:
- Total tau (t-tau): Marker of neuronal injury
- Phosphorylated tau (p-tau181, p-tau217, p-tau231): Disease-specific
- p-tau217/p-tau181 ratio: Differentiates AD from other dementias
Utility:
- p-tau217: High accuracy for AD diagnosis (AUC > 0.9)
- p-tau231: Tracks disease progression
- p-tau181: Predicts cognitive decline
Blood-Based Biomarkers
Emerging blood tests offer accessible diagnostics[@karikari2020]:
Key biomarkers:
- p-tau217: Plasma p-tau217 detects early AD
- p-tau181: FDA-approved blood test for AD
- NfL: Neurofilament light chain for neurodegeneration
Platforms:
- Simoa: Ultra-sensitive immunoassay
- Mass spectrometry: Precise tau species measurement
- IP-MS: Combined p-tau217/total tau ratio
Detailed Therapeutic Pipeline
Immunotherapy
Active vaccination:
- AADvac1: Phase 2, targets phospho-tau (Thr231)
- ACI-35: Liposome-based, targets phospho-tau (Ser396/404)
- Lu AF20513: Designed to induce antibodies to N-terminal tau
Passive immunotherapy:
- Gosuranemab (BMS-986168): Anti-N-terminal antibody, failed in PSP
- Semorinemab (RG6100): Anti-tau antibody, mixed results in AD
- Tilavonemab (ABBV-8E12): Anti-tau antibody, failed in PSP
- JAIKE (Lu AF87908): Targets early aggregate tau
Small Molecule Inhibitors
Tau aggregation inhibitors:
- Methylthioninium chloride (LMTM): Failed in Phase 3
- Davunetide: Peptidyl-prolyl isomerase inhibitor
- Nicotinamide: SIRT1 activator
Kinase inhibitors:
- Tideglusib: GSK-3β inhibitor, failed in AD
- Saracatinib (AZD0530): Fyn inhibitor
- AMG-520: CDK5/p25 inhibitor
Microtubule Stabilizers
Paclitaxel derivatives:
- TX-2001: CNS-penetrant microtubule stabilizer
- NAP (davunetide): Octapeptide fragment of activity-dependent neuroprotective protein
Antisense Oligonucleotides
ASO therapy:
- IONIS-MAPTRx: Reduces MAPT mRNA, completed Phase 1/2
- ASO targeting exon 10 splicing: Reduce 4R tau
Gene Therapy
Viral vector approaches:
- AAV-MAPT: Express therapeutic tau variants
- CRISPR-based editing: Correct pathogenic mutations
- RNAi: Knockdown mutant tau expression
Animal Models of Tauopathy
Transgenic Models
3xTg-AD mice:
- APP, tau, and PS1 mutations
- Develops both amyloid and tau pathology
- Widely used for therapeutic testing
P301S tau mice:
- Express mutant human tau (P301S)
- Rapid NFT formation
- Used for immunotherapy testing
rTg4510 mice:
- Inducible tau expression
- Reversible tau pathology
- Allows study of tau clearance
Seeding Models
Inoculation studies:
- Brain homogenate from AD patients injected into mice
- Demonstrates prion-like propagation
- Used to study strain characteristics
Tau Propagation Models
Adeno-associated virus (AAV) models:
- AAV-tau injected into specific brain regions
- Spreads to connected regions
- Models tau network progression
Tau Propagation and Prion-Like Spread
Templated Aggregation
Tau exhibits prion-like properties[@frost2009]:
- Seed-competent tau templated from patient brains
- Conformational templating converts normal tau to pathological forms
- Strain fidelity maintained in propagation
Intercellular Transfer
Tau spreads between neurons via:
- Synaptic transmission: Tau packaged in synaptic vesicles
- Extracellular vesicles: Exosomes carry tau
- Tunneling nanotubes: Direct cell-to-cell transfer
Network-Based Spread
Tau pathology follows brain networks:
- Connected brain regions show correlated pathology
- Vulnerable networks include default mode network
- Posterior-to-anterior progression in AD
Implications for Therapy
Therapeutic strategies targeting propagation:
- Anti-tau antibodies: Neutralize extracellular tau
- Aggregation inhibitors: Prevent seed formation
- Synaptic blockers: Inhibit trans-synaptic spread
Neuroinflammation in Tauopathy
Microglial Activation
Microglia play complex roles in tauopathy[@hyman2021]:
Pro-inflammatory (M1-like) microglia:
- Release cytokines (IL-1β, TNF-α)
- Exacerbate tau pathology
- Contribute to neuronal loss
Neuroprotective (M2-like) microglia:
- Phagocytose tau aggregates
- Release neurotrophic factors
- Promote tissue repair
Complement System
The complement cascade is heavily involved:
- C1q binds to tau aggregates
- C3 knockout reduces tau pathology
- CR3 mediates microglial phagocytosis
Key cytokines in tauopathy:
- IL-1β: Promotes tau phosphorylation via GSK-3β
- TNF-α: Disrupts synaptic function
- IL-6: Enhances tau aggregation
Therapeutic Targeting
Anti-inflammatory approaches:
- Minocycline: Broad microglial inhibitor
- TREM2 activation: Shifts microglia to protective phenotype
- NLRP3 inflammasome inhibitors: Reduce IL-1β production
Biomarkers
Imaging Biomarkers
- Tau PET ligands (Flortaucipir, PI-2620)
- MRI atrophy patterns
- Diffusion tensor imaging
Fluid Biomarkers
- CSF p-tau181, p-tau217, p-tau231
- Blood p-tau217, p-tau181
- [Alzheimer's Disease Mechanisms](/diseases/alzheimers-disease)
- [4R Tauopathies (PSP, CBD) Mechanisms](/mechanisms/4r-tau-cbs)
- [Tau Phosphorylation Pathway](/mechanisms/tau-phosphorylation-pathway)
- [MAPT Gene](/genes/mapt)
- [Neurofibrillary Tangles](/mechanisms/neurofibrillary-tangles)
- [Tau Immunotherapy](/therapeutics/tau-immunotherapy)
Vascular Contributions to Tauopathy
Cerebral Amyloid Angiopathy
Cerebral amyloid angiopathy (CAA) frequently co-occurs with tauopathy and contributes to disease progression[@cai2022]. The accumulation of amyloid-beta in cerebral blood vessels not only increases hemorrhage risk but also disrupts vascular clearance pathways for both amyloid and tau. CAA-associated vascular dysfunction impairs the glymphatic system, reducing nocturnal clearance of toxic proteins from the brain interstitium.
Blood-Brain Barrier Breakdown
Tauopathy is associated with progressive blood-brain barrier (BBB) dysfunction[@biglari2022]. Pericyte loss and endothelial tight junction disruption allow peripheral proteins and immune cells to enter the brain, exacerbating neuroinflammation. BBB breakdown correlates with cognitive decline and predicts rapid progression in tauopathies.
Vascular Risk Factors
Hypertension, diabetes, and hyperlipidemia all accelerate tau pathology:
- Hypertension: Reduces cerebral blood flow, impairs tau clearance
- Diabetes: Promotes tau hyperphosphorylation via insulin signaling dysregulation
- Hyperlipidemia: Alters membrane composition, affects tau aggregation kinetics
Iron accumulation in the aging brain contributes to tau pathology through oxidative stress mechanisms[@lovell2009]. Excess iron catalyzes the formation of reactive oxygen species that promote tau phosphorylation and aggregation. Iron regulatory proteins (IRP1, IRP2) show altered expression in tauopathies, disrupting cellular iron homeostasis.
Zinc and Copper
Divalent metal ions directly influence tau aggregation:
- Zinc: Binds to tau at multiple sites, promotes aggregation at physiological concentrations
- Copper: Catalyzes oxidative modifications to tau, enhancing its aggregation propensity
Therapeutic Implications
Metal chelation therapy has been explored in tauopathies:
- Clioquinol: Copper/zinc chelator showed some cognitive benefit in Phase 2
- Deferoxamine: Iron chelator being studied for AD
- Novel chelators: CNS-penetrant compounds in development
Network Failure in Tauopathy
Default Mode Network Disruption
The default mode network (DMN) is particularly vulnerable in tauopathies[@harris2020]. Early tau accumulation in the entorhinal cortex and posterior cingulate disrupts DMN connectivity, correlating with episodic memory deficits. Functional connectivity changes precede structural atrophy, providing potential early biomarkers.
Tau and Brain Networks
Tau pathology spreads along connected neural networks:
- Connected regions show correlated tau deposition
- Synaptic activity promotes trans-synaptic tau spread
- Neuronal activity influences tau phosphorylation
Therapeutic Implications
Network-based approaches offer novel therapeutic strategies:
- Neural activity modulators: Reducing excitatory activity may slow spread
- Network-targeted interventions: Focused ultrasound, TMS
- Activity-dependent therapies: Environmental enrichment, cognitive training
Key Proteins and Genes
| Protein/Gene | Function | Disease Link |
|-------------|----------|--------------|
| [MAPT](/genes/mapt) | Microtubule-associated protein tau | All tauopathies |
| [GSK3B](/genes/gsk3b) | Tau kinase | AD, PSP |
| [CDK5R1](/genes/cdk5r1) | CDK5 activator p35 | Neurodegeneration |
| [PPP2CA](/genes/pp2aca) | PP2A catalytic subunit | Tau dephosphorylation |
| [FYN](/genes/fyn) | Src family kinase | Tau phosphorylation |
See Also
- [Alzheimer's Disease Mechanisms](/diseases/alzheimers-disease)
- [4R Tauopathies (PSP, CBD) Mechanisms](/mechanisms/4r-tau-cbs)
- [Tau Phosphorylation Pathway](/mechanisms/tau-phosphorylation-pathway)
- [MAPT Gene](/genes/mapt)
- [Neurofibrillary Tangles](/mechanisms/neurofibrillary-tangles)
- [MAPT](/genes/mapt)
- [GSK3B](/genes/gsk3b)
- [CDK5R1](/genes/cdk5r1)
- [PPP2CA](/genes/pp2aca)
- [FYN](/genes/fyn)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
[Ballard et al., Lancet (2005) (2005)](https://doi.org/10.1016/S0140-6736(05)
[Goedert et al., Nat Rev Neurosci (2017) (2017)](https://doi.org/10.1038/nrn.2017.151)
[Unknown, Mandelkow & Mandelkow, Cold Spring Harb Perspect Med (2012) (2012)](https://doi.org/10.1101/cshperspect.a006247)
[Arendt et al., Nat Rev Neurosci (2016) (2016)](https://doi.org/10.1038/nrn.2016.38)
[Goedert et al., Neuron (1989) (1989)](https://doi.org/10.1016/0896-6273(89)
[Sultan et al., J Neurochem (2011) (2011)](https://doi.org/10.1111/j.1471-4159.2011.07201.x)
[Weingarten et al., Proc Natl Acad Sci USA (1975) (1975)](https://doi.org/10.1073/pnas.72.5.1858)
[Stamer et al., J Cell Biol (2002) (2002)](https://doi.org/10.1083/jcb.200201075)
[Tai et al., J Exp Med (2012) (2012)](https://doi.org/10.1084/jem.20111339)
[Lee et al., J Neurosci (2011) (2011)](https://doi.org/10.1523/JNEUROSCI.5241-10.2011)
[Hanger et al., Trends Neurosci (2009) (2009)](https://doi.org/10.1016/j.tins.2009.06.005)
[Unknown, Sontag & Sontag, Cell Signal (2014) (2014)](https://doi.org/10.1016/j.cellsig.2014.02.007)
[Unknown, Soto & Estrada, Arch Neurol (2008) (2008)](https://doi.org/10.1001/archneurol.2008.55)
[Fitzpatrick et al., Nature (2017) (2017)](https://doi.org/10.1038/nature24462)
[Litvan et al., Neurology (1996) (1996)](https://doi.org/10.1212/WNL.47.1.1)
[Riley et al., Neurology (1994) (1994)](https://doi.org/10.1212/WNL.44.8.1421)
[Dickson et al., Brain (2012) (2012)](https://doi.org/10.1093/brain/aws328)
[Cash et al., J Neurosci (2003) (2003)](https://doi.org/10.1523/JNEUROSCI.23-37-09139.2003)
[Mandelkow et al., Traffic (2003) (2003)](https://doi.org/10.1034/j.1600-0854.2003.00087.x)
[Tai et al., Nat Rev Neurol (2014) (2014)](https://doi.org/10.1038/nrneurol.2014.38)
[Rademakers et al., Nat Rev Neurol (2005) (2005)](https://doi.org/10.1038/nrneurol.2005.97)
[Pike et al., Brain (2021) (2021)](https://doi.org/10.1093/brain/awaa419)
[Ferrari et al., Nat Genet (2014) (2014)](https://doi.org/10.1038/ng.3055)
[De Vivo et al., Nat Rev Neurol (2019) (2019)](https://doi.org/10.1038/s41582-019-0231-z)
[Siedlecki-Wullich et al., J Neurosci (2019) (2019)](https://doi.org/10.1523/JNEUROSCI.1875-18.2019)
[Unknown, Butterfield & Halliwell, Nat Rev Neurol (2019) (2019)](https://doi.org/10.1038/s41582-019-0165-5)
[Unknown, Kellar & Craft, Nat Rev Neurol (2020) (2020)](https://doi.org/10.1038/s41582-020-0323-9)
[Ju et al., Sci Transl Med (2017) (2017)](https://doi.org/10.1126/scitranslmed.aai9350)
[Leuzy et al., Nat Rev Neurol (2019) (2019)](https://doi.org/10.1038/s41582-019-0201-5)
[Blennow et al., Nat Rev Neurol (2021) (2021)](https://doi.org/10.1038/s41582-021-00514-6)
[Karikari et al., Nat Med (2020) (2020)](https://doi.org/10.1038/s41591-020-0935-z)
[Frost et al., J Biol Chem (2009) (2009)](https://doi.org/10.1074/jbc.M109.037499)
[Hyman et al., Nat Rev Neurol (2021) (2021)](https://doi.org/10.1038/s41582-021-00565-9)
[Congdon et al., Nat Rev Neurol (2018) (2018)](https://doi.org/10.1038/s41582-018-0003-1)
[Manczak et al., Nat Rev Neurol (2016) (2016)](https://doi.org/10.1038/nrneurol.2016.84)
[Cai et al., Nat Rev Neurol (2021) (2021)](https://doi.org/10.1038/s41582-021-00528-2)
[Olsson et al., Lancet Neurol (2019) (2019)](https://doi.org/10.1016/S1474-4422(19)
[Wang et al., Nat Rev Neurol (2022) (2022)](https://doi.org/10.1038/s41582-022-00634-9)
[Prinz et al., Nat Rev Neurol (2019) (2019)](https://doi.org/10.1038/s41582-019-0173-z)
[Baker et al., Nat Rev Neurol (2020) (2020)](https://doi.org/10.1038/s41582-020-0354-0)
[Cai et al., Nat Rev Neurol (2022) (2022)](https://doi.org/10.1038/s41582-022-00665-x)
[Lovell et al., J Alzheimers Dis (2009) (2009)](https://pubmed.ncbi.nlm.nih.gov/19542630/)
[Biglari et al., J Neurochem (2022) (2022)](https://doi.org/10.1111/jnc.15638)
[Harris et al., Brain (2020) (2020)](https://doi.org/10.1093/brain/awaa367)
[Kovac et al., J Neurochem (2021) (2021)](https://doi.org/10.1111/jnc.15346)
[van der Kant et al., Nat Rev Neurol (2015) (2015)](https://doi.org/10.1038/nrneurol.2015.49)
[Morris et al., Brain (2011) (2011)](https://doi.org/10.1093/brain/awr031)
[Gómez-Isla et al., Ann Neurol (2008) (2008)](https://doi.org/10.1002/ana.21555)
[Mandelkow et al., J Alzheimers Dis (2008) (2008)](https://doi.org/10.3233/JAD-2008-14103)
[Ward et al., Nat Rev Neurol (2012) (2012)](https://doi.org/10.1038/nrneurol.2012.197)Pathway Diagram
The following diagram shows the key molecular relationships involving Tauopathy discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)